Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and ...
MedPage Today

GLP-1 Drugs Tied to Unexpected Migraine Benefits

Chronic migraineurs who started GLP-1 drugs also were 14% less likely to be hospitalized (RR 0.86, 95% CI 0.81-0.91), and ...

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but ...

Eli Lilly's weight-loss pill shows higher side effects than Novo rival in diabetes trial

Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...

Lilly’s New Weight‑Loss Pill Shows Double the Results of Novo Nordisk’s GLP-1 Rival in a Major Study

Lilly’s new data show its oral GLP-1 beating Novo’s on major benchmarks.
Everyday Health on MSN

New GLP-1 Pill for Diabetes Shows Strong Results in Late-Stage Trial

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

Wegovy and Ozempic Will Cost Less in 2027. Here Are the New Slashed Prices

The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a ...

Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs

Feb 25 (Reuters) - Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion ...

Head-to-head trial shows Eli Lilly’s oral GLP-1 orforglipron outperforms oral semaglutide

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...